PHi Token’s objective is to become the first wealth management platform for both traditional than crypto assets based on blockchain technology. Our community-centric approach aims to revolution traditional investments with the introduction of crypto related products. All PHI token holders will have the opportunity to participate in the development of the PHI network through the concept of “proof of stake” and also benefit 30% discount in the purchasing of Financial services directly in the Platform for Hybrid Investment (PHI). Our community will benefit of the increasing request for PHI Tokens connected to the increasing of services, software and financial providers and also the increase of the community. At the moment, there are no European fintech startups with those tailor-made investment services connecting the traditional investments to crypto assets, and also there aren’t financial management company that use the blockchain for a more trasparent and secure data management as DIAMAN Partners (the management company under approval by MFSA are doing). PHI is also a open platform for the distribution of financial instruments and services, that means many Asset Managers, Financial Advisors, Wealth Managers will benefit of this fully digitalize platform and they will stake a lot of PHI Token to become partners of the project. All our Members of the community that own PHI Token can access to our professional financial software as a PRO, in a freemium version of software until today reserved to institutional clients only, and can easly compare the best in class Asset Manager around the world to increse their expected return and gain their goal with a higher probability.

PHI Token

PHI Token is a decentralized investment platform.

CryptoRank Premium

Add New {name} Alert

Moves above

Moves below

Coin tracking

ATH Reached

change abs

change %

Price Range

Unusual volume

Please connect your account to our Telegram bot to receive notifications

New price alert added

Check your email

We've sent you an email with confirmation link. If you don't have it in your inbox - check your spam box.

CryptoRank App

See CryptoRank with...

You need to click on the button below and start the opened bot

Choose a convenient way to connect your EVM wallet.

Privacy & Terms Agreement

Market Data API

Track your wallet balances, view asset allocations, get real-time price data, and more

Easily manage your assets with our Mobile App

Join and earn by referring new subscribers!

Explore blockchain platforms: ecosystem projects, TVL, and other key metrics

Name

Complete tasks and earn rewards

CryptoRank Spaceships

Select Websites channels that you want to add to Cryptonews feed

Select Sources

Please enter your valid email address to proceed with registration.

Sorry, but your {social} account doesn't have an email address.

IDO/ICO analytics: post-listing ROI and launchpad comparisons.

Track project announcements and campaigns. Spot early opportunities so you don’t miss airdrops and rewards.

Exchanges overview: volumes, listings, market share.

Track rounds, stages, and amounts. See investors and fund portfolios.

Monitor DeFi & NFT, positions and P&L. Popular chains and a mobile app supported.

Lite gives core tools ad-free. Premium adds advanced analytics, full tables, and exclusives.

TGE calendar and vesting flow. Analyze unlock volumes and percentages to gauge supply pressure and plan your moves.

Get in touch with us for info about listings, tokens, exchanges, IDOs, or any other promotional inquires

Interested in a partnership?

Payments are processed by Heleket. Use only the supported chains/tokens. CryptoRank cannot compensate for failed transactions made on an unsupported blockchain.

Advanced Tools and Ad-Free Experience for In-Depth Analysis

Payments are processed by Paddle. Use only the supported payment methods. CryptoRank cannot compensate for failed or incomplete transactions made outside of supported options.

Receive Comprehensive Analytics, Exclusive Research, and Guides

Payment confirmed

Add promocode

Total Due:

Improves token ranking and increases exposure.

Visibility Boost

Accelerates momentum and helps stay in trending.

Trending Score Growth

Boost Benefits

Boost visibility, raise the Trending Score, and unlock the Premium Ticker for {symbol}!

Purchasing a Boost does not guarantee a specific ranking or position. CryptoRank makes no representations or guarantees regarding the impact of Boost on asset visibility. All purchases are final and non-refundable.

Want to learn more about Boost? <link>Check out the guide!</link>

Give {name} a {boost}

Subject

The account is suspected of violating CryptoRank.io terms of use. You may continue to use the website except for personal features.

Your account has been suspended

By accessing and using our Site, you confirm that you are at least 18 years old or the legal age of majority in your jurisdiction. Please also ensure you have read and agree to our Terms of Use and Privacy Policy & Cookies Statement

Stay updated with the latest news, social media updates, and information about %name%. Gain valuable insights into market trends and stay informed about the vibrant community discussions.

%name%: Latest News, Social Media Updates and Insights

Current AI debates regarding booming vendor revenue and high failure rates miss the real question of: Who is actually getting value from AI? In this guest commentary, Ganesh Padmanabhan of Autonomize AI, provides a rundown of ways to determine whether your AI creates value or simply revenue noise.

Crunchbase

AI Revenue Is Not Value — And ‘95% Failure’ Misses The Real Story

Pharos iBio, a pharmaceutical company specializing in AI-driven drug development, witnessed a significant surge in its shares after announcing the therapeutic use approval of PHI-101, a revolutionary treatment for relapsed or refractory acute myeloid leukemia (AML). The approval, granted by the Ministry of Food and Drug Safety, marks a groundbreaking moment for the pharmaceutical industry ... Read more

PHI TokenPHI

Latest PHI Token News and Social Media Feed

AI Revenue Is Not Value — And ‘95% Failure’ Misses The Real Story

AI-Driven Drug Approval Propels Pharos iBio Shares to New Heights